
Keywords: HCV; hepatitis C; LT; liver transplantation; DDI; drug-drug interactions; DAAs; direct-acting antivirals; PegINF; peginterferon; RBV; ribavirin; MELD; model of end-stage liver disease; PI; protease inhibitor; PR; peginterferon plus ribavirin; SAEs; seriou